eFFECTOR Therapeutics- Warrants (26/08/2026) Accounts Payable

The latest accounts payable for EFTRW is $120K as of March 2026. That compares with $37K in the prior-year period — up 227.7% year over year. Investors often review this figure alongside eFFECTOR Therapeutics- Warrants (26/08/2026)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, EFTRW's accounts payable moved from $37K to $120K — a 227.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in eFFECTOR Therapeutics- Warrants (26/08/2026)'s operating scale or balance-sheet position.

A accounts payable figure of $120K for EFTRW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting EFTRW's accounts payable ($120K), review year-over-year change from $37K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack eFFECTOR Therapeutics- Warrants (26/08/2026)'s accounts payable against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.